Epigenuity is a physician-scientist-founded research company developing decision-support software and diagnostic platforms across maternal health, oncology, and acute care.
"The hardest problems in medicine aren't in the lab — they're in the workflow gap between evidence and bedside. We build the bridge."
Prospective validation of a serum glycodelin (PAEP) clinical laboratory-developed test paired with the EndoTwin-W computational model, for personalized timing of frozen embryo transfer in IVF cycles. CLIA/CAP laboratory partner and validation IVF clinics in development.
Investigational research-use only. Not FDA-cleared. CLIA LDT in development.
Across decision-support software, diagnostics, devices, and computational platforms. Programs are at different stages — from in-market product (PPHrisk) to preclinical (Cas13 liquid biopsy) to validated computational models (EndoTwin-W).
Stage indicators are directional. Summary validation data for EndoTwin-W is public via endotwin-w.com and bioRxiv. Selected technical details for other programs available to partners under CDA.
Every Epigenuity program starts with a workflow problem observed at the bedside, not a technology looking for an application. We validate clinically before we engineer commercially.
Programs originate from real clinical gaps — bundle non-compliance, missed early AKI, late-detected breast cancer. We solve what hurts.
In-house bench science (Cas13, RT-RPA, bioimpedance) paired with ovine and human validation. Phase-gated development.
Every program has a defined go-to-market path: 510(k), LDT, software, or strategic licensing. No moonshots without a path to patients.
Practicing physicians and scientists with a track record in translational research.
Vice Chair of Research, OB/GYN · Tenured Professor · University of Arizona College of Medicine
NIH-funded physician-scientist with $14M+ in PI funding across NICHD, NHLBI, and NIEHS portfolios. Vice Chair of Research in the Department of Obstetrics and Gynecology at the University of Arizona, with active R01s in maternal-fetal cerebrovascular biology and developmental epigenetics. Founded Epigenuity to translate workflow insights from L&D and the ICU into deployable decision-support and diagnostic products.
We're assembling an SAB with deep expertise in maternal-fetal medicine, oncology, and digital health.
Interested in advising? →Active collaborations with the University of Arizona, Banner Health, and clinical partners across the Southwest.
Open to new partnerships →Across six active programs, Epigenuity is preparing federal STTR / SBIR applications, formalizing institutional partnerships, and filing IP. Summary validation data is public for EndoTwin-W; selected technical details available to qualified partners under CDA.
STTR Fast Track in preparation for serum glycodelin (PAEP) CLIA laboratory-developed test paired with EndoTwin-W decision support for frozen embryo transfer timing. Prospective IVF clinic validation in design phase.
University of Arizona as research institution partner. Active engagement with UA Tech Launch Arizona (TLA) regarding licensing of inventions developed under university affiliation. Licensing in negotiation.
Identifying and engaging a CLIA/CAP-certified clinical laboratory partner for the serum glycodelin (PAEP) laboratory-developed test underlying the EndoTwin-W assay workflow. Discussions in progress.
Decision-support software with 30-day free trial, individual subscriptions, and L&D Team Edition in early access. EndoTwin-W computational platform live at endotwin-w.com. Two of six programs already in market.
Active provisional applications covering EndoTwin-W methodology, Smart Pessary technology, critical-care monitoring, and assay platform design. Non-provisional conversions in progress.
Founder Dr. Ravi Goyal (MD, PhD, MBA, FAHA) has a decade-plus history of NIH funding across NICHD, NHLBI, and NIEHS portfolios, including active R01 awards. AHA Fellow, study section reviewer (15+ AHA panels, 4+ NIH committees). Vice Chair of Research, UA OB/GYN.
Selected technical details available to qualified partners under CDA. Summary validation data on EndoTwin-W is available at endotwin-w.com and bioRxiv.
Founder bibliography spans maternal-fetal physiology, vascular biology, IUGR, developmental epigenetics, traumatic brain injury, and translational medicine — including a 94-page review in Physiological Reviews (2018).
Whether you're a clinical collaborator, investor, prospective hire, advisor, or someone from a federal agency or foundation — we want to hear from you.